New Prospects for Matrix Metalloproteinase Targeting in Cancer Therapy

Matrix Proteases in Health and Disease

Volumn , Issue , 2012, Pages 373-387

  Buache, Emilie ^a   Rio, Marie Christine ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

hemopexin domain; metalloproteinase targeting; monoclonal antibody; spatiotemporal function; tumorigenesis; zinc binding groups

Indexed keywords

EID: 84885829248     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527649327.ch15     Document Type: Chapter

References (108)

1. Bissell, M.J., Radisky, D.C., Rizki, A., Weaver, V.M., and Petersen, O.W. (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation, 70, 537-546.
2. Radisky, D., Muschler, J., and Bissell, M.J. (2002) Order and disorder: the role of extracellular matrix in epithelial cancer. Cancer Invest., 20, 139-153.
3. De Wever, O. and Mareel, M. (2003) Role of tissue stroma in cancer cell invasion. J. Pathol., 200, 429-447.
4. Freije, J.M., Balbin, M., Pendas, A.M., Sanchez, L.M., Puente, X.S., and Lopez-Otin, C. (2003) Matrix metalloproteinases and tumor progression. Adv. Exp. Med. Biol., 532, 91-107.
5. Mueller, M.M. and Fusenig, N.E. (2004) Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer, 4, 839-849.
6. Maquart, F.X., Bellon, G., Pasco, S., and Monboisse, J.C. (2005) Matrikines in the regulation of extracellular matrix degradation. Biochimie, 87, 353-360.
7. Basset, P., Bellocq, J.P., Wolf, C., Stoll, I., Hutin, P., Limacher, J.M., Podhajcer, O.L., Chenard, M.P., Rio, M.C., and Chambon, P. (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature, 348, 699-704.
8. Basset, P., Okada, A., Chenard, M.P., Kannan, R., Stoll, I., Anglard, P., Bellocq, J.P., and Rio, M.C. (1997) Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol., 15, 535-541.
9. Birkedal-Hansen, H. (1995) Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol., 7, 728-735.
10. Itoh, Y. and Seiki, M. (2006) MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell Physiol., 206, 1-8.
11. Lochter, A., Sternlicht, M.D., Werb, Z., and Bissell, M.J. (1998) The significance of matrix metalloproteinases during early stages of tumor progression. Ann. N. Y. Acad. Sci., 857, 180-193.
12. Jodele, S., Blavier, L., Yoon, J.M., and DeClerck, Y.A. (2006) Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev., 25, 35-43.
13. Nagase, H., Visse, R., and Murphy, G. (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res., 69, 562-573.
14. Kessenbrock, K., Plaks, V., and Werb, Z. (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67.
15. Masson, R., Lefebvre, O., Noel, A., Fahime, M.E., Chenard, M.P., Wendling, C., Kebers, F., LeMeur, M., Dierich, A., Foidart, J.M. et al. (1998) In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol., 140, 1535-1541.
16. Sternlicht, M.D., Bissell, M.J., and Werb, Z. (2000) The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene, 19, 1102-1113.
17. Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2, 737-744.
18. Goss, K.J., Brown, P.D., and Matrisian, L.M. (1998) Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int. J. Cancer, 78, 629-635.
19. Noel, A., Hajitou, A., L'Hoir, C., Maquoi, E., Baramova, E., Lewalle, J.M., Remacle, A., Kebers, F., Brown, P., Calberg-Bacq, C.M., and Foidart, J.M. (1998) Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int. J. Cancer, 76, 267-273.
20. Rudolph-Owen, L.A., Chan, R., Muller, W.J., and Matrisian, L.M. (1998) The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res., 58, 5500-5506.
21. Zucker, S., Cao, J., and Chen, W.T. (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene, 19, 6642-6650.
22. Overall, C.M. and Lopez-Otin, C. (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer, 2, 657-672.
23. Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295, 2387-2392.
24. Pavlaki, M. and Zucker, S. (2003) Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev., 22, 177-203.
25. Noel, A., Jost, M., and Maquoi, E. (2008) Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol., 19, 52-60.
26. Fingleton, B. (2008) in The Cancer Degradome (ed. D.R. Edwards), Springer Science, pp. 757-783.
27. Dorman, G., Cseh, S., Hajdu, I., Barna, L., Konya, D., Kupai, K., Kovacs, L., and Ferdinandy, P. (2010) Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs, 70, 949-964.
28. Visse, R. and Nagase, H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 92, 827-839.
29. Baker, A.H., Zaltsman, A.B., George, S.J., and Newby, A.C. (1998) Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Invest., 101, 1478-1487.
30. Clutterbuck, A.L., Asplin, K.E., Harris, P., Allaway, D., and Mobasheri, A. (2009) Targeting matrix metalloproteinases in inflammatory conditions. Curr. Drug Targets, 10, 1245-1254.
31. Whittaker, M., Floyd, C.D., Brown, P., and Gearing, A.J. (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 99, 2735-2776.
32. Cuniasse, P., Devel, L., Makaritis, A., Beau, F., Georgiadis, D., Matziari, M., Yiotakis, A., and Dive, V. (2005) Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie, 87, 393-402.
33. Nuti, E., Tuccinardi, T., and Rossello, A. (2007) Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des., 13, 2087-2100.
34. Tu, G., Xu, W., Huang, H., and Li, S. (2008) Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem., 15, 1388-1395.
35. Maskos, K. and Bode, W. (2003) Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Mol. Biotechnol., 25, 241-266.
36. Rao, B.G. (2005) Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des., 11, 295-322.
37. Dive, V., Georgiadis, D., Matziari, M., Makaritis, A., Beau, F., Cuniasse, P., and Yiotakis, A. (2004) Phosphinic peptides as zinc metalloproteinase inhibitors. Cell Mol. Life Sci., 61, 2010-2019.
38. Floquet, N., Marechal, J.D., Badet-Denisot, M.A., Robert, C.H., Dauchez, M., and Perahia, D. (2006) Normal mode analysis as a prerequisite for drug design: application to matrix metalloproteinases inhibitors. FEBS Lett., 580, 5130-5136.
39. Devel, L., Czarny, B., Beau, F., Georgiadis, D., Stura, E., and Dive, V. (2010) Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1_ cavity. Biochimie, 92, 1501-1508.
40. Dublanchet, A.C., Ducrot, P., Andrianjara, C., O'Gara, M., Morales, R., Compere, D., Denis, A., Blais, S., Cluzeau, P., Courte, K. et al. (2005) Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg. Med. Chem. Lett., 15, 3787-3790.
41. Engel, C.K., Pirard, B., Schimanski, S., Kirsch, R., Habermann, J., Klingler, O., Schlotte, V., Weithmann, K.U., and Wendt, K.U. (2005) Structural basis for the highly selective inhibition of MMP-13. Chem. Biol., 12, 181-189.
42. Pochetti, G., Montanari, R., Gege, C., Chevrier, C., Taveras, A.G., and Mazza, F. (2009) Extra binding region induced by non-zinc chelating inhibitors into the S1_ subsite of matrix metalloproteinase 8 (MMP-8). J. Med. Chem., 52, 1040-1049.
43. Golub, L.M., Sorsa, T., Lee, H.M., Ciancio, S., Sorbi, D., Ramamurthy, N.S., Gruber, B., Salo, T., and Konttinen, Y.T. (1995) Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J. Clin. Periodontol., 22, 100-109.
44. Lokeshwar, B.L. (2010) Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol. Res., 63, 145-150.
45. Mannello, F. (2006) Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Pat. Anticancer Drug Discov., 1, 91-103.
46. Sternlicht, M.D. and Werb, Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 17, 463-516.
47. Pei, D. and Weiss, S.J. (1995) Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature, 375, 244-247.
48. Bassi, D.E., Mahloogi, H., and Klein-Szanto, A.J. (2000) The proprotein convertases furin and PACE4 play a significant role in tumor progression. Mol. Carcinog., 28, 63-69.
49. Bregant, S., Huillet, C., Devel, L., Dabert-Gay, A.S., Beau, F., Thai, R., Czarny, B., Yiotakis, A., and Dive, V. (2009) Detection of matrix metalloproteinase active forms in complex proteomes: evaluation of affinity versus photoaffinity capture. J. Proteome Res., 8, 2484-2494.
50. Dabert-Gay, A.S., Czarny, B., Devel, L., Beau, F., Lajeunesse, E., Bregant, S., Thai, R., Yiotakis, A., and Dive, V. (2008) Molecular determinants of matrix metalloproteinase-12 covalent modification by a photoaffinity probe: insights into activity-based probe development and conformational variability of matrix metalloproteinases. J. Biol. Chem., 283, 31058-31067.
51. Scherer, R.L., McIntyre, J.O., and Matrisian, L.M. (2008) Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev., 27, 679-690.
52. Bremer, C., Tung, C.H., and Weissleder, R. (2001) In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat. Med., 7, 743-748.
53. Littlepage, L.E., Sternlicht, M.D., Rougier, N., Phillips, J., Gallo, E., Yu, Y., Williams, K., Brenot, A., Gordon, J.I., and Werb, Z. (2010) Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res., 70, 2224-2234.
54. Olson, E.S., Aguilera, T.A., Jiang, T., Ellies, L.G., Nguyen, Q.T., Wong, E.H., Gross, L.A., and Tsien, R.Y. (2009) In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb), 1, 382-393.
55. Chenard, M.P., O'Siorain, L., Shering, S., Rouyer, N., Lutz, Y., Wolf, C., Basset, P., Bellocq, J.P., and Duffy, M.J. (1996) High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer, 69, 448-451.
56. Delebecq, T.J., Porte, H., Zerimech, F., Copin, M.C., Gouyer, V., Dacquembronne, E., Balduyck, M., Wurtz, A., and Huet, G. (2000) Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin. Cancer Res., 6, 1086-1092.
57. Hahnel, E., Dawkins, H., Robbins, P., and Hahnel, R. (1994) Expression of stromelysin-3 and nm23 in breast carcinoma and related tissues. Int. J. Cancer, 58, 157-160.
58. Kawami, H., Yoshida, K., Ohsaki, A., Kuroi, K., Nishiyama, M., and Toge, T. (1993) Stromelysin-3 mRNA expression and malignancy: comparison with clinicopathological features and type IV collagenase mRNA expression in breast tumors. Anticancer Res., 13, 2319-2323.
59. Kossakowska, A.E., Huchcroft, S.A., Urbanski, S.J., and Edwards, D.R. (1996) Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br. J. Cancer, 73, 1401-1408.
60. Muller, D., Wolf, C., Abecassis, J., Millon, R., Engelmann, A., Bronner, G., Rouyer, N., Rio, M.C., Eber, M., Methlin, G. et al. (1993) Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res., 53, 165-169.
61. Polette, M., Clavel, C., Birembaut, P., and De Clerck, Y.A. (1993) Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol. Res. Pract., 189, 1052-1057.
62. Soni, S., Mathur, M., Shukla, N.K., Deo, S.V., and Ralhan, R. (2003) Stromelysin-3 expression is an early event in human oral tumorigenesis. Int. J. Cancer, 107, 309-316.
63. Peruzzi, D., Mori, F., Conforti, A., Lazzaro, D., De Rinaldis, E., Ciliberto, G., La Monica, N., and Aurisicchio, L. (2009) MMP11: a novel target antigen for cancer immunotherapy. Clin. Cancer Res., 15, 4104-4113.
64. Ma, X.J., Dahiya, S., Richardson, E., Erlander, M., and Sgroi, D.C. (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res., 11, R7.
65. Hannemann, J., Velds, A., Halfwerk, J.B., Kreike, B., Peterse, J.L., and van de Vijver, M.J. (2006) Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res., 8, R61.
66. Yang, Y.H., Deng, H., Li, W.M., Zhang, Q.Y., Hu, X.T., Xiao, B., Zhu, H.H., Geng, P.L., and Lu, Y.Y. (2008) Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling. Clin. Cancer Res., 14, 74-81.
67. Noel, A.C., Lefebvre, O., Maquoi, E., VanHoorde, L., Chenard, M.P., Mareel, M., Foidart, J.M., Basset, P., and Rio, M.C. (1996) Stromelysin-3 expression promotes tumor take in nude mice. J. Clin. Invest., 97, 1924-1930.
68. Boulay, A., Masson, R., Chenard, M.P., El Fahime, M., Cassard, L., Bellocq, J.P., Sautes-Fridman, C., Basset, P., and Rio, M.C. (2001) High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res., 61, 2189-2193.
69. Wu, E., Mari, B.P., Wang, F., Anderson, I.C., Sunday, M.E., and Shipp, M.A. (2001) Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J. Cell Biochem., 82, 549-555.
70. Andarawewa, K.L., Boulay, A., Masson, R., Mathelin, C., Stoll, I., Tomasetto, C., Chenard, M.P., Gintz, M., Bellocq, J.P., and Rio, M.C. (2003) Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res., 63, 5844-5849.
71. Brasse, D., Mathelin, C., Leroux, K., Chenard, M.P., Blaise, S., Stoll, I., Tomasetto, C., and Rio, M.C. (2010) Matrix metalloproteinase 11/stromelysin-3 exerts both activator and repressor functions during the hematogenous metastatic process in mice. Int. J. Cancer, 127, 1347-1355.
72. Overall, C.M. and Kleifeld, O. (2006) Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer, 6, 227-239.
73. Lopez-Otin, C. and Matrisian, L.M. (2007) Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer, 7, 800-808.
74. Kruger, A., Kates, R.E., and Edwards, D.R. (2010) Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim. Biophys. Acta, 1803, 95-102.
75. Rio, M.C. (2005) From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie, 87, 299-306.
76. McCawley, L.J. and Matrisian, L.M. (2001) Matrix metalloproteinases: they're not just for matrix anymore!. Curr. Opin. Cell Biol., 13, 534-540.
77. VanSaun, M.N. and Matrisian, L.M. (2006) Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res.C Embryo Today, 78, 69-79.
78. Fiorentino, M., Fu, L., and Shi, Y.B. (2009) Mutational analysis of the cleavage of the cancer-associated laminin receptor by stromelysin-3 reveals the contribution of flanking sequences to site recognition and cleavage efficiency. Int. J. Mol. Med., 23, 389-397.
79. Andarawewa, K.L., Motrescu, E.R., Chenard, M.P., Gansmuller, A., Stoll, I., Tomasetto, C., and Rio, M.C. (2005) Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res., 65, 10862-10871.
80. Motrescu, E.R. and Rio, M.C. (2008) Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol. Chem., 389, 1037-1041.
81. Motrescu, E.R., Blaise, S., Etique, N., Messaddeq, N., Chenard, M.P., Stoll, I., Tomasetto, C., and Rio, M.C. (2008) Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene, 27, 6347-6355.
82. Dirat, B., Bochet, L., Escourrou, G., Valet, P., and Muller, C. (2010) Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocr. Dev., 19, 45-52.
83. Andarawewa, K.L. and Rio, M.C. (2008) in The Cancer Degradome (ed. D.R. Edwards), Springer Science, pp. 353-364.
84. Mueller, M., and Fusenig, N. (2011) The role of Cancer-Associated Adipocytes (CAA) in the dynamic interaction between the tumor and the host, Springer SBM, Springer Science, pp. 111-123.
85. Mitsiades, N., Yu, W.H., Poulaki, V., Tsokos, M., and Stamenkovic, I. (2001) Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res., 61, 577-581.
86. Manes, S., Mira, E., Barbacid, M.M., Cipres, A., Fernandez-Resa, P., Buesa, J.M., Merida, I., Aracil, M., Marquez, G., and Martinez, A.C. (1997) Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem., 272, 25706-25712.
87. Carey, K.D., Schwall, R.H., and Sliwkowski, M.X. (2006) Inhibiting HER2 shedding with MMP antagonists. Patent WO/2006/086730.
88. Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res., 61, 4744-4749.
89. Abbenante, G. and Fairlie, D.P. (2005) Protease inhibitors in the clinic. Med. Chem., 1, 71-104.
90. Dive, V., Andarawewa, K.L., Boulay, A., Matziari, M., Beau, F., Guerin, E., Rousseau, B., Yiotakis, A., and Rio, M.C. (2005) Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases. Int. J. Cancer, 113, 775-781.
91. Peterson, J.T. (2006) The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res., 69, 677-687.
92. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 29, 15-18.
93. Demicheli, R. (2001) Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin. Cancer Biol., 11, 297-306.
94. Corbitt, C.A., Lin, J., and Lindsey, M.L. (2007) Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat. Anticancer Drug Discov., 2, 135-142.
95. Glasheen, B.M., Kabra, A.T., and Page-McCaw, A. (2009) Distinct functions for the catalytic and hemopexin domains of a Drosophila matrix metalloproteinase. Proc. Natl. Acad. Sci. U. S. A., 106, 2659-2664.
96. Dufour, A., Zucker, S., Sampson, N.S., Kuscu, C., and Cao, J. (2010) Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J. Biol. Chem., 285, 35944-35956.
97. Redondo-Munoz, J., Ugarte-Berzal, E., Terol, M.J., Van den Steen, P.E., Hernandez del Cerro, M., Roderfeld, M., Roeb, E., Opdenakker, G., Garcia-Marco, J.A., and Garcia-Pardo, A. (2010) Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell, 17, 160-172.
98. Eisenach, P.A., Roghi, C., Fogarasi, M., Murphy, G., and English, W.R. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J. Cell Sci., 123, 4182-4193.
99. Houghton, A.M., Hartzell, W.O., Robbins, C.S., Gomis-Ruth, F.X., and Shapiro, S.D. (2009) Macrophage elastase kills bacteria within murine macrophages. Nature, 460, 637-641.
100. Kothapalli, R., Khan, A.M., Basappa, Gopalsamy, A., Chong, Y.S., and Annamalai, L. (2010) Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain. PLoS ONE, 5, e12494.
101. Kenny, H.A. and Lengyel, E. (2009) MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle, 8, 683-688.
102. Galvez, B.G., Matias-Roman, S., Albar, J.P., Sanchez-Madrid, F., and Arroyo, A.G. (2001) Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem., 276, 37491-37500.
103. Devy, L., Huang, L., Naa, L., Yanamandra, N., Pieters, H., Frans, N., Chang, E., Tao, Q., Vanhove, M., Lejeune, A. et al. (2009) Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res., 69, 1517-1526.
104. Devy, L. and Dransfield, D.T. (2011) New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem. Res. Int., 2011, 191670.
105. Hofmeister, V., Schrama, D., and Becker, J.C. (2008) Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother., 57, 1-17.
106. Yi, T., Tian, L., Su, J.M., Liu, J., and Wei, Y.Q. (2004) Constructing the tumor cell vaccine based on homologous matrix metalloproteinase-2 and exploring its effects. Sichuan Da Xue Xue Bao Yi Xue Ban, 35, 301-304.
107. Yokoyama, Y., Grunebach, F., Schmidt, S.M., Heine, A., Hantschel, M., Stevanovic, S., Rammensee, H.G., and Brossart, P. (2008) Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin. Cancer Res., 14, 5503-5511.
108. Liu, S., Wang, H., Currie, B.M., Molinolo, A., Leung, H.J., Moayeri, M., Basile, J.R., Alfano, R.W., Gutkind, J.S., Frankel, A.E. et al. (2008) Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J. Biol. Chem., 283, 529-540.